江湖电竞赛程手机版
GRF
ES
0.60
5.05%
Closed
€ 12.47
| Previous Close |
|---|
| €11.87 |
Volume: 1.68M
65 Day Avg: 982.31K
11.92
Day Range
12.66
11.26
52 Week Range
22.64
Overview
GRF Overview
Key Data
- Open €11.94
- Day Range 11.92 - 12.66
- 52 Week Range 11.26 - 22.64
- Market Cap €7.07B
- Shares Outstanding N/A
- Public Float 291.77M
- Beta N/A
- Rev. per Employee €212.22K
- P/E Ratio N/A
- EPS N/A
- Yield 0.00%
- Dividend €0.30
- Ex-Dividend Date Jun 3, 2021
- Short Interest N/A
- % of Float Shorted N/A
- Average Volume 982.31K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
3
Full Ratings
Recent News
Novartis sells diagnostics unit for $1.68 billion
LONDON (江湖电竞最新版比赛(江湖电竞投注app网站)) -- Novartis AG has agreed to sell its blood-transfusion diagnostics unit to Spain's Grifols SA for $1.675 billion in cash, the Swiss pharmaceutical giant said Monday. "The sale ... enables us to focu...
Europe edges higher after bin Laden’s death
Danisco surges on higher DuPont offer; TNT down after results
Europe ends lower for second straight session
European equity benchmarks trade lower to start the week, extending losses from the previous session, with miners notably weaker as investors fret about global economic-growth trends.
Grifols to acquire Talecris for $3.4 billion
Spain’s Grifols SA to acquire Talecris Biotherapeutics Holdings Corp. for $3.4 billion, forming a global producer of plasma protein therapies.
New Grifols shares in Talecris deal are non-voting
Talecris shares closed Friday at $15.92
Grifols to pay indicated $26.16 per Talecris share
Grifols to pay $19, 0.641 share per Talecris share
Talecris to be acquired by Grifols for $3.4B
Grifols S.A.
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Baxter International Inc. |
|
CHF35.47B |
| Almirall S.A. |
|
€1.62B |